BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-treated Participants in the ATTR-ACT Study Near-complete Stabilization of TTR Maintained in Participants Throughout Duration of Study […]

BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

-Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolio -Delivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy type 2i -Ended quarter with $446.1 million in cash, cash equivalents and marketable securities, excluding Eidos Recent Highlights: BBP-831 – FGFR1-3 inhibitor for achondroplasia: Initiated PROPEL, a prospective observational study in children with […]

BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference

Preclinical data shows promise for gene therapy candidates for congenital adrenal hyperplasia due to 21-hydroxylase deficiency (BBP-631) and Canavan disease (BBP-812) Natural history clinical study for Canavan disease is currently enrolling IND submissions for both gene therapy product candidates anticipated in 2020 SAN FRANCISCO – October 22, 2019 – BridgeBio Pharma, Inc. (NASDAQ:BBIO) today announced […]

QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia

Data presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting Infigratinib showed improvements in nine measures of bone development in the Fgfr3Y367C/+ mouse model of achondroplasia at a low dose Observational study (The PROPEL Trial) is currently enrolling children age 2.5-10 years and planned submission of an investigational new drug application remains […]